BRPI0413323A - processo para a preparação de vacinas conjugadas de polissacarìdeo-proteìna - Google Patents

processo para a preparação de vacinas conjugadas de polissacarìdeo-proteìna

Info

Publication number
BRPI0413323A
BRPI0413323A BRPI0413323-4A BRPI0413323A BRPI0413323A BR PI0413323 A BRPI0413323 A BR PI0413323A BR PI0413323 A BRPI0413323 A BR PI0413323A BR PI0413323 A BRPI0413323 A BR PI0413323A
Authority
BR
Brazil
Prior art keywords
preparation
polysaccharide
protein
protein conjugate
conjugate vaccines
Prior art date
Application number
BRPI0413323-4A
Other languages
English (en)
Inventor
Ellen Jessouroun
Ivna Alana Freitas Br Silveira
Renata Chagas Bastos
Carl E Frasch
Che-Hung Robert Lee
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of BRPI0413323A publication Critical patent/BRPI0413323A/pt
Publication of BRPI0413323B1 publication Critical patent/BRPI0413323B1/pt
Publication of BRPI0413323B8 publication Critical patent/BRPI0413323B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"PROCESSO PARA A PREPARAçãO DE VACINAS CONJUGADAS DE POLISSACARìDEO-PROTEìNA". Métodos para a preparação de vacinas conjugadas de polissacarídeo-proteína em produção elevada, são fornecidos. Os métodos envolvem a reação de um grupo de hidrazida em um reagente com um grupo de aldeído no outro reagente. A reação prossegue rapidamente com uma eficiência elevada de conjugação. Os processos de purificação simplificados podem ser empregados para separar o produto conjugado do polissacarídeo e proteína não conjugados e outros subprodutos de molécula pequena.
BRPI0413323A 2003-08-06 2004-08-06 método para a preparação de uma vacina meningocócica conjugada ao toxóide tetânico em volumes comerciais BRPI0413323B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49338903P 2003-08-06 2003-08-06
PCT/US2004/026431 WO2005037320A2 (en) 2003-08-06 2004-08-06 Process for preparing polysaccharide-protein conjugate vaccines

Publications (3)

Publication Number Publication Date
BRPI0413323A true BRPI0413323A (pt) 2006-10-10
BRPI0413323B1 BRPI0413323B1 (pt) 2019-09-10
BRPI0413323B8 BRPI0413323B8 (pt) 2021-05-25

Family

ID=34135243

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0413309A BRPI0413309B8 (pt) 2003-08-06 2004-08-06 método para a preparação de uma vacina conjugada de polissacarídeo-proteína
BRPI0413323A BRPI0413323B8 (pt) 2003-08-06 2004-08-06 método para a preparação de uma vacina meningocócica conjugada ao toxóide tetânico em volumes comerciais

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0413309A BRPI0413309B8 (pt) 2003-08-06 2004-08-06 método para a preparação de uma vacina conjugada de polissacarídeo-proteína

Country Status (8)

Country Link
US (1) US9173931B2 (pt)
EP (4) EP2366403B1 (pt)
CN (4) CN102151331B (pt)
AU (2) AU2004263135B2 (pt)
BR (2) BRPI0413309B8 (pt)
CA (4) CA2844154C (pt)
WO (2) WO2005014037A2 (pt)
ZA (2) ZA200601689B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
CA2844154C (en) 2003-08-06 2016-12-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US9402915B2 (en) * 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
WO2005117965A1 (en) * 2004-06-04 2005-12-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing immunogenic conjugates
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425853A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
LT2351578T (lt) * 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
CN101405028B (zh) 2006-03-17 2015-08-19 美国政府健康及人类服务部 制备复合的多价免疫原性结合物的方法
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP2043692B1 (en) 2006-07-25 2016-05-18 Lipoxen Technologies Limited Polysaccharide derivatives of erythropoietin
US8003112B2 (en) 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
EP2493510B1 (en) * 2009-09-30 2020-07-08 GlaxoSmithKline Biologicals SA Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN102526724B (zh) * 2011-01-14 2015-07-22 四川大学 氢氧化铝凝胶-多糖复合免疫佐剂及其制备方法和用途
WO2013177397A1 (en) 2012-05-24 2013-11-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Multivalent meningococcal conjugates and methods for preparing cojugates
EP2724730A1 (en) 2012-10-29 2014-04-30 Institut Pasteur Glycoconjugates and their use as potential vaccines against infection by Shigella Flexneri
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
US12616744B2 (en) 2014-01-21 2026-05-05 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
SI3096783T1 (sl) * 2014-01-21 2021-09-30 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
CN104198725B (zh) * 2014-08-14 2016-04-06 上海睿康生物科技有限公司 抗环瓜氨酸肽抗体检测试剂盒
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CA2988366C (en) * 2015-06-08 2021-12-07 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof.
US20170333546A1 (en) * 2015-12-08 2017-11-23 Jl Medical Corporation Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
RS65362B1 (sr) 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR20240018698A (ko) 2017-06-10 2024-02-13 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2019126197A1 (en) 2017-12-18 2019-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacterial polysaccharide-conjugated carrier proteins and use thereof
CN108525003A (zh) * 2018-03-13 2018-09-14 中山大学 基于酰腙键和亲疏水自组装的双交联杂化水凝胶、其制备方法及皮肤组织创面修复剂
CN108498847A (zh) * 2018-03-13 2018-09-07 中山大学 基于酰腙键的高分子水凝胶、其制备方法及皮肤组织粘附剂
CN109001198A (zh) * 2018-09-03 2018-12-14 艾美卫信生物药业（浙江）有限公司 脱氧胆酸钠沉淀法检测Hib结合疫苗中游离多糖的方法
EP4192499A4 (en) 2020-08-10 2024-09-25 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
CN113274489B (zh) * 2021-04-30 2023-08-29 山东省药学科学院 一种预防真菌感染的几丁质寡糖疫苗及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen
JPS63295408A (ja) * 1987-05-28 1988-12-01 Mitsubishi Gas Chem Co Inc 水加ヒドラジン水溶液の精製方法
US5066408A (en) * 1990-03-15 1991-11-19 Powell Jonathan S Means and method to treat swimming pool water
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5480643A (en) * 1991-10-16 1996-01-02 Ecolab Inc. Stable antimicrobial dialdehyde composition and methods of use
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
AU712981B2 (en) * 1995-03-22 1999-11-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US6800728B2 (en) * 2000-03-22 2004-10-05 Solulink Biosciences, Inc. Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US20050014037A1 (en) * 2002-12-04 2005-01-20 Chris Boyer Fuel cell with recombination catalyst
CA2844154C (en) 2003-08-06 2016-12-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines

Also Published As

Publication number Publication date
CA2844154C (en) 2016-12-20
AU2004281630A1 (en) 2005-04-28
CN103623405B (zh) 2016-06-15
CN102151331A (zh) 2011-08-17
CN100423774C (zh) 2008-10-08
CA2534870C (en) 2014-05-06
CN102151331B (zh) 2013-10-30
BRPI0413309B1 (pt) 2019-10-01
EP2366403A2 (en) 2011-09-21
EP1651261B1 (en) 2014-10-08
EP2366404A3 (en) 2012-03-14
US9173931B2 (en) 2015-11-03
EP1651262A2 (en) 2006-05-03
BRPI0413323B1 (pt) 2019-09-10
EP1651261A2 (en) 2006-05-03
BRPI0413309B8 (pt) 2021-05-25
CN1863553A (zh) 2006-11-15
US20070110762A1 (en) 2007-05-17
EP2366403A3 (en) 2012-03-14
EP2366404A2 (en) 2011-09-21
ZA200601688B (en) 2007-05-30
ZA200601689B (en) 2007-12-27
BRPI0413323B8 (pt) 2021-05-25
CA2535043A1 (en) 2005-04-28
CN1863554A (zh) 2006-11-15
BRPI0413309A (pt) 2006-10-10
AU2004263135B2 (en) 2010-11-25
WO2005014037A2 (en) 2005-02-17
CN1863553B (zh) 2011-05-04
EP2366404B1 (en) 2014-11-19
HK1195512A1 (zh) 2014-11-14
WO2005037320A3 (en) 2006-01-05
CA2844154A1 (en) 2005-02-17
AU2004263135A1 (en) 2005-02-17
WO2005037320A2 (en) 2005-04-28
CN103623405A (zh) 2014-03-12
CA2534870A1 (en) 2005-02-17
CA2948114C (en) 2019-02-26
CA2948114A1 (en) 2005-02-17
WO2005014037A3 (en) 2006-01-26
EP2366403B1 (en) 2014-10-08

Similar Documents

Publication Publication Date Title
BRPI0413309A (pt) vacinas conjugadas de polissacarida -proteìna
AR048035A1 (es) Conjugados de almidon de hidroxialquilo y una proteina, preparados por aminacion reductora
EA200701022A1 (ru) Химический синтез, направляемый структурной нуклеиновой кислотой
DE602004007620D1 (de) Lipophile derivate doppelsträngiger ribonukleinsäure
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
BRPI0612654B8 (pt) método para conjugar um sacarídeo a uma proteína, e, conjugado sacarídeo-proteína
BRPI0416546A (pt) produção de ácido 3-hidroxipropiÈnico usando beta-alanina/piruvato aminotransferase
ATE430558T1 (de) Herstellung von mikrokügelchen
BRPI0507540A (pt) processo para a produção de conjugados de polissacarìdeos e polinucleotìdeos
EA200601168A1 (ru) КОНЪЮГАТЫ Aβ ИММУНОГЕННЫХ ПЕПТИДНЫХ НОСИТЕЛЕЙ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EP1808180A3 (en) Modified GP 100 and uses thereof
MXPA05006702A (es) Hemoglobina modificada y metodos para hacer la misma.
DE60119711D1 (de) Verfahren zur herstellung von funktionalierten polyalkyleniminen, diese enthaltende zusammenstellungen und ihre verwendungen
BR0213774A (pt) Molécula de ácido nucleio isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
DE502004001922D1 (de) Verfahren zur herstellung von ethylenaminen
BR0213779A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
GB2446088B (en) Production of conjugates
ATE300516T1 (de) Derivatisierung von trägeroberflächen
BR0213773A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
EP1907419A4 (en) PREPARATION OF INSULIN CONJUGATES
ITMI20041271A1 (it) Processo di preparazione di gabapentina
TW200510287A (en) Modafinil synthesis process
DE60314904D1 (de) Verfahren zur herstellung von chinoloncarboxylat-derivaten
PT1064265E (pt) Sintese de 3-amino-2-cloro-4-metilpiridina a partir de malononitrilo e acetona
BR0213772A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 47/48, A61P 37/00

Ipc: C07D 209/04 (2011.01), C07D 265/30 (2011.01), C07D

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A RETRIBUICAO DA(S) 12A. ANUIDADE(S), DE ACORDO COM TABELA VIGENTE, REFERENTE A(S) GUIA(S) DE RECOLHIMENTO 22150845038-7.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) ; FUNDACAO OSWALDO CRUZ (BR/RJ)

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICA-SE O DEFERIMENTO NOTIFICADO NA RPI 2530 DE 02/07/2019.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2846 DE 22/07/2025 POR TER SIDO INDEVIDA.